Clinical Trials Logo

Clinical Trial Summary

Children between the ages of 6-12 years who are diagnosed with impulsive aggression comorbid with ADHD and have participated in the 810P301 or 810P302 study were invited to participate in this study. This was a Phase 3 open-label extension (OLE) study to collect long-term safety data on the use of SPN-810 in treating impulsive aggression in pediatric subjects with ADHD when taken in conjunction with standard ADHD treatment. After confirmation of eligibility, all subjects were treated with SPN-810. Subjects were given a choice to extend participation in this study every 6 months for up to 36 months.


Clinical Trial Description

Study 810P304 is a multicenter, open-label, extension study aimed to assess safety of SPN-810 in the treatment of IA in patients aged 6-17 years with ADHD in conjunction with standard ADHD treatment. The study has three phases: Optimization, Maintenance, and Taper. All subjects who complete the randomized, double-blind portion of study 810P301, 810P302, 810P503 or 810P204 will have the option to participate in the OLE study in which all subjects will receive active Study Medication (SM) treatment. Subjects who choose to participate in the OLE will receive blinded conversion medication kits at Visit 6 of the previous SPN-810 double-blind randomization study (810P301, 810P302) or at Visit 4 for subjects completing the 810P204 study. Subjects, who have completed the 810P503 study and, chose to participate in this study, will receive the blinded conversion card at Visit 7. ;


Study Design


Related Conditions & MeSH terms

  • Aggression
  • Attention Deficit Disorder with Hyperactivity
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Hyperkinesis

NCT number NCT02691182
Study type Interventional
Source Supernus Pharmaceuticals, Inc.
Contact
Status Terminated
Phase Phase 3
Start date April 2016
Completion date May 2021

See also
  Status Clinical Trial Phase
Completed NCT03260205 - Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD) Phase 3
Withdrawn NCT03546400 - Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD. Phase 4
Completed NCT02917109 - LearningRx Cognitive Training for ADHD N/A
Completed NCT02248948 - Superiority of Omega-3 Versus Placebo on the Improvement of ADHD in Children N/A
Recruiting NCT01750307 - The Relationship of Essential Fatty Acids to Adult ADHD: The OCEAN Study (Oils and Cognitive Effects in Adult ADHD Neurodevelopment) N/A
Recruiting NCT06170996 - Internet-Assisted Behavioral Parent Training Intervention for Children With Attention Deficit Hyperactivity Disorder N/A
Completed NCT00735371 - Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 3
Withdrawn NCT03580005 - A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD. Phase 4
Completed NCT02578030 - Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD Phase 1
Completed NCT02574273 - Pilot Trial of a Social Skills Group Treatment (Secret Agent Society Program) N/A
Completed NCT02257216 - Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD) N/A
Recruiting NCT04943796 - A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life
Recruiting NCT04634006 - Home-Based tDCS in Children With ADHD: A Randomized, Sham-Controlled tDCS and fNIRS Study N/A
Active, not recruiting NCT02908802 - Probiotic Supplement as Treatment for Students With ADHD N/A
Completed NCT02604407 - Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD) Phase 3
Completed NCT05870605 - Drug Use Study With Intuniv® in European Countries
Terminated NCT03481959 - Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity Phase 3
Terminated NCT03638466 - Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With Attention-Deficit/Hyperactivity Disorder Phase 2
Completed NCT03709940 - Brain Connectivity in Attention Deficit Hyperactivity Disorder (ADHD) N/A
Completed NCT02795637 - Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction Phase 1